ROCKVILLE, Md., Jan. 30, 2025 (GLOBE NEWSWIRE) -- ., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing solutions to advance the discovery, development and ...

(Alliance News) - MaxCyte Inc on Thursday said it has acquired SeQure Dx Inc, as it looks to improve its gene therapy testing process. The Rockville, Maryland-based cell therapy developer paid an ...

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

MaxCyte announced on Thursday that it has acquired SeQure Dx, a specialist in on-target and off-target editing assessment services for cell and gene therapies, in a move aimed at broadening its ...

In a report released today, Matt Hewitt from Craig-Hallum assigned a Buy rating to MaxCyte (MXCT – Research Report). The company’s shares ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...

Columnist Joe MacDonald, who'll soon move to a new city, appreciates the care from his therapist to treat his "hemophilia dad" anxieties.

Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation ...

REGENXBIO Inc. today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at ...

The World Health Organization said on Thursday that over 2,000 people have been wounded by fighting in and around Congo's city of Goma and 45 people have died, citing unnamed reports. "There are ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.